Related Experiment Video

Updated: Oct 2, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Pharmacotherapy of dyslipidemia

J M McKenney1

  • 1School of Pharmacy, Medical College of Virginia, Virginia Commonwealth University, USA. jmckenney@ncrinc.net

Cardiovascular Drugs and Therapy
|February 22, 2002
PubMed

Insights

Lowering low-density-lipoprotein cholesterol (LDL-C) is crucial for reducing coronary heart disease (CHD) risk. Statins are primary treatments, but combination therapy may be needed for severe hyperlipidemia.

Area of Science:

  • Cardiology
  • Pharmacology
  • Metabolic Disorders

Background:

  • Elevated low-density-lipoprotein cholesterol (LDL-C) is a major risk factor for coronary heart disease (CHD).
  • Despite established guidelines, achieving target LDL-C levels remains a challenge for many hypercholesterolemic patients.
  • Drug therapy is often necessary to reach target LDL-C levels.

Purpose of the Study:

  • To review the different types of dyslipidemia.
  • To assess the most effective pharmacological treatments for hyperlipidemia.
  • To emphasize the importance of LDL-C reduction in preventing CHD events.

Main Methods:

  • Review of current literature on dyslipidemia management.
  • Assessment of lipid-lowering drug classes including statins, fibrates, niacin, and resins.
  • Evaluation of treatment efficacy based on lipid-lowering abilities, safety, and tolerability.

Main Results:

  • Statins are the first-line pharmacotherapeutic agents due to their efficacy in lowering LDL-C and reducing CHD events and mortality.
  • Statin monotherapy is effective for moderate hypertriglyceridemia with elevated LDL-C.
  • Fibrates or niacin are indicated for severe hypertriglyceridemia, while resins offer an alternative for isolated hypercholesterolemia or specific patient groups.

Conclusions:

  • Achieving target LDL-C levels is essential for CHD risk reduction in hypercholesterolemic patients.
  • Statins are the cornerstone of lipid-lowering therapy.
  • Combination drug therapy may be required for severe or refractory hyperlipidemia.

More Related Videos

Self-Nanoemulsification of Healthy Oils to Enhance the Solubility of Lipophilic Drugs08:18

Self-Nanoemulsification of Healthy Oils to Enhance the Solubility of Lipophilic Drugs

Published on: July 27, 2022

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...